EPR in Pharma

Pharmaceutical Applications of EPR

Paramagnetic Impurity Profiling

All drugs contain impurities that can arise from the drug substances (APIs) or inert materials (excipients). They are also introduced into the drug product during the formulation processes, packaging, and storage. Impurities have many unwanted effects, such as:

  • Decreasing the therapeutic effect
  • Lowering the product shelf-life
  • Inducing toxicity

Identification, quantification, and control of impurities in API and the drug product are critical in drug development. Organic impurities are often free radicals from by-products, intermediates, or degradation products. Inorganic impurities include transition metals, reagents, and ligands.

Please complete the form to access the documents

View our updated Privacy & Cookie Policy.

Dear Sir/Madam,

Thank you for your interest in quantitative EPR in pharma. We hope you find the documents informative. If we can be of further assistance, please contact us.

Best regards,
Your Bruker Team